Clinical trials: Adverse Effect
Tumor Infiltrating Lymphocytes, Safety
A Phase I Study of GC101 TIL in Advanced Solid Tumors
20-60 participants are expected to be enrolled for the Phase I clinical trial which is further divided into two parts: a "3+3" dose escalation study and an expanded enrollment study.
- Conditions
- Tumor Infiltrating Lymphocytes, Safety, Advanced Solid Tumor, Immunotherapy
- Trial name
- MIZAR-001 (NCT05417750)
- Testing
- TIL therapy
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Shanghai Juncell Therapeutics
Cardiotoxicity, Cancer
Mazankowski Alberta Heart Institute (MAHI) EchoGo Discovery 1 Protocol
This study aims to compare conventionally acquired Left Ventricle Ejection Fraction (LVEF) and Global Longitudinal Strain (GLS) data to Artificial Intelligence (AI) driven automated processing of 2 dimensional contrast and 2…
- Trial name
- NCT04877899
- Testing
- EchoGo
- Where
- Canada
- Volunteers
- 250 people
- Sponsor
- Ultromics Ltd
Pain, Osteoarthritis, Hip
Placebo-controlled Trial With OROS Hydromorphone Hydrochloride to Treat Patients With Moderate to Severe Pain Induced by Osteoarthritis of the Hip or the Knee
This clinical trial tests the pain relieving effectiveness of OROS hydromorphone, a once-daily formulation of a strong opioid against placebo in patients, who are suffering from pain due to osteoarthritis of the hip or the knee…
- Conditions
- Pain, Osteoarthritis, Hip, Osteoarthritis, Knee
- Trial name
- NCT00980798
- Testing
- OROS hydromorphone HCl
- Where
- 12 sites in Czechia, Romania and 2 more
- Volunteers
- 288 people
- Sponsor
- Janssen-Cilag International NV
HER2-low Hormone Receptor Positive Breast Cancer
A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients
This is a Phase II Study of HLX22 in Combination with Trastuzumab Deruxtecan (T-DXd) in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients with Disease Progression or Intolerable Adverse…
- Trial name
- NCT06832202
- Testing
- HLX22, Trastuzumab Deruxtecan
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Henlius Biotech
Stevens-Johnson Syndrome, Graft Versus Host Disease in Eye
Evaluation of Tangible Boost for Patients With Stevens Johnson Syndrome, Sjogren's Syndrome, and Graft Vs Host Disease
The goal of this research is to determine if the Tangible Boost system adequately replenishes the Hydra-PEG coating on the surface of a rigid contact lens.
- Conditions
- Stevens-Johnson Syndrome, Graft Versus Host Disease in Eye, Sjogren's Syndrome, Dry Eye
- Trial name
- NCT04313725
- Testing
- Tangible Boost
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Tangible Science
Small Cell Lung Cancer, Soft Tissue Sarcoma
Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.
Tinostamustine (EDO-S101) is a first-in-class alkylating deacetylase inhibitor designed to improve drug access to deoxyribonucleic acid (DNA) strands, induce DNA damage and counteract its repair in cancer cells.
- Conditions
- Small Cell Lung Cancer, Soft Tissue Sarcoma, Triple-negative Breast Cancer, Ovarian Cancer
- Trial name
- EDO-S101 (NCT03345485)
- Testing
- Tinostamustine 60mg/m2 over 30min, Tinostamustine 80mg/m2 over 30min, Tinostamustine 100mg/m2 over 30min
- Where
- 13 sites in United States, Canada and 3 more
- Volunteers
- 71 people
- Sponsor
- Mundipharma Research Limited
Physician Education
A Phase 4 Study of Regorafenib in Metastatic Colorectal Cancer - Does Educating Physicians Change Patient Outcomes?
Randomized trial to evaluate impact of healthcare provider( clinician and nursing staff) support and education on treatment discontinuation rates in the absence of progression in patients with metastatic colorectal cancer treated…
- Trial name
- SMART (NCT02287025)
- Testing
- Regorafenib (Stivarga, BAY73-4506), iPAD application, Bayer specialist
- Where
- 17 sites in United States
- Volunteers
- 23 people
- Sponsor
- Bayer
Healthy Volunteers
Study to Assess Safety and Tolerability of KarXT With Administration of Antiemetics in Healthy Volunteers
This study looks at how to reduce nausea and vomiting in people taking KarXT which is used to treat mental health conditions like schizophrenia.
- Trial name
- NCT07681076
- Testing
- KarXT, Trimethobenzamide, Ondansetron
- Where
- 4 sites in United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Cardiovascular Disease, High Cardiovascular Risk
A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study in overweight and obese subjects with cardiovascular (CV) disease and/or multiple CV risk factors.
- Conditions
- Cardiovascular Disease, High Cardiovascular Risk, Obesity, Overweight
- Trial name
- CAMELLIA-TIMI (NCT02019264)
- Testing
- Lorcaserin hydrochloride
- Where
- 499 sites in United States, Australia and 6 more
- Volunteers
- 14,673 people
- Sponsor
- Eisai Inc.
Carcinoid Syndrome
Real-world Evidence Study EvaLuating PAtient-Reported Outcomes With XERMELO
The primary objective of the study is to estimate the proportion of carcinoid syndrome (CS) patients who are satisfied with their overall symptom control, 6 months after initiating treatment with telotristat ethyl (XERMELO).
- Trial name
- RELAX (NCT03223428)
- Testing
- Xermelo
- Where
- United States
- Volunteers
- 223 people
- Sponsor
- TerSera Therapeutics LLC
Cancer, Heart Failure
A Multicenter Clinical Trial on DH001 Tablets in the Prevention of Doxorubicin-induced Cardiotoxicity in Cancer Patients
Purpose：1. Preliminary evaluation of the preventive effect of DH001 on doxorubicin-induced cardiotoxicity in cancer patients 2.To explore appropriate dosages to provide basis for dosages in subsequent confirmatory studies 3.To…
- Conditions
- Cancer, Heart Failure, Arrhythmia, Doxorubicin Induced Cardiomyopathy
- Trial name
- NCT06092606
- Testing
- Trial group: DH001 low-dose group, Trial group: DH001 high-dose group
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Monyan Pharmaceutical (Shanghai) Co., Ltd.
Advanced Gynecologic Tumors, Signal Switch Receptor Modified TIL
A Study of GC201 TIL in Advanced Gynecologic Tumors (10hospital)
This study is to investigate the safety and efficacy of signal switch receptor modified TIL (GC201 TIL) in patients with advanced gynecologic tumors.
- Conditions
- Advanced Gynecologic Tumors, Signal Switch Receptor Modified TIL, Treatment Side Effects, Effects of Immunotherapy
- Trial name
- NCT05098171
- Testing
- Signal Switch Receptor Modified TIL
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Juncell Therapeutics
Oral Mucositis
Polyphenol Rich Aerosol as a Support for Cancer Patients in Minimizing Side Effects After a Radiation Therapy
The aim of the study is to demonstrate in a clinical condition the effectiveness of a preparation that is a mixture of plant extracts rich in polyphenolic compounds in the aspect of supporting cancer patients in minimizing side…
- Trial name
- NCT05994638
- Testing
- Aerosol (Polyphenol-rich plant extracts, Hyaluronic Acid, Cetraria Islandica, Vitamin B3)
- Where
- Poland
- Volunteers
- 10 people
- Sponsor
- AronPharma Sp. z o. o.
HIV Infections
Comparing Side Effects of Two Forms of Videx in HIV-Infected Adults
The purpose of this study is to compare gastrointestinal (stomach and intestines) side effects of 2 forms of Videx in HIV-infected patients.
- Trial name
- NCT00008489
- Testing
- Didanosine
- Where
- 15 sites in United States
- Volunteers
- 200 people
- Sponsor
- PharmaResearch
Chronic Kidney Disease, Type 2 Diabetes Mellitus
A Study Using Surveys to Learn More About Treatment With Steroidal Mineralocorticoid Receptor Antagonists, How They Are Used, What Side Effects They Have, and How Satisfied People Who Receive Them Are in the US
This is an observational study in which patients with chronic kidney diseases (CKD), type 2 diabetes (T2D) or heart failure (HF) who are current or past users of sMRA therapies are studied.
- Conditions
- Chronic Kidney Disease, Type 2 Diabetes Mellitus, Heart Failure
- Trial name
- NCT05407662
- Testing
- sMRA therapies
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Bayer
Dry Eye Disease
Research Study To See How Well An Eye Drop (SURF-200) Works, What Side Effects There Are, And To Compare It With Vehicle In Subjects With An Episodic Flare-Up of Dry Eye Disease
SURF-200 is being studied in people experiencing an episodic flare-up of their dry eye disease. SURF-200 is an investigational drug (which means the study drug is currently being tested) in the form of a sterile eye drop.
- Trial name
- NCT04734210
- Testing
- 0.02% Betamethasone Sodium Phosphate, 0.04% Betamethasone Sodium Phosphate
- Where
- 28 sites in United States
- Volunteers
- 139 people
- Sponsor
- Surface Ophthalmics, Inc.
Ventilator Adverse Event, Ventilator Associated Pneumonia
Effect of Angulus on Patient-elevation Compliance
Ventilator-associated events (VAE) are a scourge of critical care settings and hospital systems at large. There is extensive evidence that ventilator-associated pneumonia (VAP) and related VAEs increase mortality rates in…
- Conditions
- Ventilator Adverse Event, Ventilator Associated Pneumonia, Hospital Acquired Condition, Hospital-acquired Pneumonia
- Trial name
- NCT03496220
- Testing
- Angulus
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Angulus, LLC
Drug-Induced Liver Injury
Risk of Acute Liver Injury in Users of Antimicrobials
Moxifloxacin is a broad-spectrum antibacterial agent used to treat common community-acquired respiratory tract infections, complicated intra-abdominal infections, and pelvic inflammatory disease.
- Trial name
- NCT01434173
- Testing
- Moxifloxacin (Avelox, BAY12-8039), Amoxicillin, Amoxicillin plus clavulanic acid, Cefuroxime, Clarithromycin, Doxycycline, Levofloxacin, Telithromycin
- Where
- United States
- Volunteers
- 1,299,056 people
- Sponsor
- Bayer
Advanced Gynecologic Tumors, TIL Engineered With Membrane-Binding Cytokine
A Study of GC203 TIL in Advanced Gynecologic Tumors (10hospital)
This study is to investigate the safety and efficacy on TIL engineered with membrane-binding cytokine (GC203 TIL) for the treatment of patients with advanced gynecologic tumors.
- Conditions
- Advanced Gynecologic Tumors, TIL Engineered With Membrane-Binding Cytokine, Treatment Side Effects, Effects of Immunotherapy
- Trial name
- NCT05468307
- Testing
- Membrane Bound Cytokine Modified TIL
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Shanghai Juncell Therapeutics
Schizophrenia
Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
The purpose of this study is to describe real-world treatment patterns, effectiveness and adverse events of adults diagnosed with schizophrenia that have initiated xanomeline and trospium chloride (KarXT) treatment in the United…
- Trial name
- NCT07379827
- Testing
- Xanomeline and trospium chloride (KarXT)
- Where
- 55 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- Bristol-Myers Squibb